- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 45 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.4: 2 residues within 4Å:- Chain A: Y.28, N.61
Ligand excluded by PLIPNAG.5: 4 residues within 4Å:- Chain A: N.122, A.123, T.124, V.127
Ligand excluded by PLIPNAG.6: 1 residues within 4Å:- Chain A: N.234
Ligand excluded by PLIPNAG.7: 2 residues within 4Å:- Chain A: E.281, N.282
Ligand excluded by PLIPNAG.8: 2 residues within 4Å:- Chain A: N.331, Q.580
Ligand excluded by PLIPNAG.9: 2 residues within 4Å:- Chain A: N.603, T.604
Ligand excluded by PLIPNAG.10: 2 residues within 4Å:- Chain A: N.616, T.618
Ligand excluded by PLIPNAG.11: 1 residues within 4Å:- Chain A: N.657
Ligand excluded by PLIPNAG.12: 2 residues within 4Å:- Chain A: N.709, G.1131
Ligand excluded by PLIPNAG.13: 3 residues within 4Å:- Chain A: N.717, Q.926, Q.1071
Ligand excluded by PLIPNAG.14: 3 residues within 4Å:- Chain A: N.801, S.803, Q.804
Ligand excluded by PLIPNAG.15: 3 residues within 4Å:- Chain A: A.706, E.1072, N.1074
Ligand excluded by PLIPNAG.16: 3 residues within 4Å:- Chain A: N.1098, H.1101, F.1103
Ligand excluded by PLIPNAG.17: 1 residues within 4Å:- Chain A: N.1134
Ligand excluded by PLIPNAG.18: 2 residues within 4Å:- Chain A: Q.115, N.165
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain B: Y.28, N.61
Ligand excluded by PLIPNAG.20: 5 residues within 4Å:- Chain B: N.121, N.122, V.126, F.192, L.226
Ligand excluded by PLIPNAG.21: 1 residues within 4Å:- Chain B: N.234
Ligand excluded by PLIPNAG.22: 2 residues within 4Å:- Chain B: E.281, N.282
Ligand excluded by PLIPNAG.23: 4 residues within 4Å:- Chain B: N.331, P.579, Q.580, L.582
Ligand excluded by PLIPNAG.24: 1 residues within 4Å:- Chain B: N.603
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain B: N.616, T.618
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain B: H.655, N.657
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain B: N.709, G.1131
Ligand excluded by PLIPNAG.28: 3 residues within 4Å:- Chain B: N.717, Q.926, Q.1071
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain B: N.801, S.803, Q.804
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain B: A.706, E.1072, N.1074
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain B: N.1098, H.1101, F.1103
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain B: N.1134
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain B: Q.115, N.165, T.167
Ligand excluded by PLIPNAG.34: 1 residues within 4Å:- Chain C: N.61
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain C: N.122, V.127
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain C: N.234
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain C: N.282
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain C: N.331, P.579, Q.580
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain C: N.603
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain C: N.616, T.618
Ligand excluded by PLIPNAG.41: 1 residues within 4Å:- Chain C: N.657
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain C: N.709, G.1131
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain C: N.717, Q.926, Q.1071
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain C: N.801, S.803, Q.804
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain C: A.706, E.1072, N.1074
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain C: N.1098, H.1101, F.1103
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain C: C.1082, N.1134
Ligand excluded by PLIPNAG.48: 4 residues within 4Å:- Chain C: Q.115, N.165, C.166, T.167
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nabel, K.G. et al., Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science (2022)
- Release Date
- 2021-12-08
- Peptides
- Spike glycoprotein: ABC
neutralizing antibody C1C-A3 heavy chain variable region: DFH
neutralizing antibody C1C-A3 light chain variable region: EGI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DF
FH
HE
EG
GI
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 45 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nabel, K.G. et al., Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science (2022)
- Release Date
- 2021-12-08
- Peptides
- Spike glycoprotein: ABC
neutralizing antibody C1C-A3 heavy chain variable region: DFH
neutralizing antibody C1C-A3 light chain variable region: EGI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DF
FH
HE
EG
GI
L